Cargando…

Cost-Effectiveness Analysis of 12-Versus 4-Weekly Administration of Bone-Targeted Agents in Patients with Bone Metastases from Breast and Castration-Resistant Prostate Cancer

A cost–utility analysis was performed based on the Rethinking Clinical Trials (REaCT) bone-targeted agents (BTA) clinical trial that compared 12-weekly (once every 12 weeks) (n = 130) versus 4-weekly (once every 4 weeks) (n = 133) BTA dosing for metastatic breast and castration-resistant prostate (C...

Descripción completa

Detalles Bibliográficos
Autores principales:	Tu, Megan M., Clemons, Mark, Stober, Carol, Jeong, Ahwon, Vandermeer, Lisa, Mates, Mihaela, Blanchette, Phillip, Joy, Anil Abraham, Aseyev, Olexiy, Pond, Gregory, Fergusson, Dean, Ng, Terry L., Thavorn, Kednapa
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2021
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8161812/ https://www.ncbi.nlm.nih.gov/pubmed/34068083 http://dx.doi.org/10.3390/curroncol28030171

Ejemplares similares

Two-year results of a randomised trial comparing 4- versus 12-weekly bone-targeted agent use in patients with bone metastases from breast or castration-resistant prostate cancer
por: Clemons, Mark, et al.
Publicado: (2021)

A randomised trial of 4- versus 12-weekly administration of bone-targeted agents in patients with bone metastases from breast or castration-resistant prostate cancer
por: Clemons, Mark, et al.
Publicado: (2021)

Perceptions around bone-modifying agent use in patients with bone metastases from breast and castration resistant prostate cancer: a patient survey
por: Alzahrani, Mashari, et al.
Publicado: (2021)

A Randomized Trial Comparing 3- versus 4-Monthly Cardiac Monitoring in Patients Receiving Trastuzumab-Based Chemotherapy for Early Breast Cancer
por: Dent, Susan, et al.
Publicado: (2021)

Effects of de-escalated bisphosphonate therapy on bone turnover biomarkers in breast cancer patients with bone metastases
por: Addison, Christina L, et al.
Publicado: (2014)

Effects on bone resorption markers of continuing pamidronate or switching to zoledronic acid in patients with high risk bone metastases from breast cancer
por: Hilton, J.F., et al.
Publicado: (2017)

Real-world practice patterns and attitudes towards de-escalation of bone-modifying agents in patients with bone metastases from breast and prostate cancer: A physician survey
por: AlZahrani, Mashari, et al.
Publicado: (2020)

Feasibility outcomes of a randomised, multicentre, pilot trial comparing standard 6-monthly dosing of adjuvant zoledronate with a single one-time dose in patients with early stage breast cancer
por: Awan, Arif, et al.
Publicado: (2020)

Prospective randomised controlled trial using the REthinking Clinical Trials (REaCT) platform and National Surgical Quality Improvement Program (NSQIP) to compare no preparation versus preoperative oral antibiotics alone for surgical site infection rates in elective colon surgery: a protocol
por: Apte, Sameer S, et al.
Publicado: (2020)

A Randomized Controlled Trial Comparing Alloderm-RTU with DermACELL in Immediate Subpectoral Implant-Based Breast Reconstruction
por: Arnaout, Angel, et al.
Publicado: (2020)

A systematic review of dosing frequency with bone-targeted agents for patients with bone metastases from breast cancer
por: Hutton, Brian, et al.
Publicado: (2013)

Doxycycline-Induced Changes in Circulating MMP or TIMP2 Levels Are Not Associated with Skeletal-Related Event-Free or Overall Survival in Patients with Bone Metastases from Breast Cancer
por: Zhao, Huijun, et al.
Publicado: (2023)

A Multi-Centre Randomized Study Comparing Two Standard of Care Chemotherapy Regimens for Lower-Risk HER2-Positive Breast Cancer
por: Fernandes, Ricardo, et al.
Publicado: (2023)

A multi-centre study comparing granulocyte-colony stimulating factors to antibiotics for primary prophylaxis of docetaxel-cyclophosphamide induced febrile neutropenia
por: Clemons, Mark, et al.
Publicado: (2021)

Detection of PIK3CA Mutations in Breast Cancer Bone Metastases
por: Daneshmand, Manijeh, et al.
Publicado: (2012)

Targeting Bone Metastases in Metastatic Castration-Resistant Prostate Cancer
por: El-Amm, Joelle, et al.
Publicado: (2016)

Current perspectives on bone metastases in castrate-resistant prostate cancer
por: Logothetis, Christopher, et al.
Publicado: (2018)

De-escalated administration of bone-targeted agents in patients with breast and prostate cancer—A survey of Canadian oncologists
por: Hutton, Brian, et al.
Publicado: (2013)

Bone-targeted agent use for bone metastases from breast cancer and prostate cancer: A patient survey
por: Hutton, Brian, et al.
Publicado: (2013)

Single-center experience with radium-223 in patients with castration-resistant prostate cancer and bone metastases
por: Kapoor, Anil, et al.
Publicado: (2019)

Randomised feasibility trial to compare three standard of care chemotherapy regimens for early stage triple-negative breast cancer (REaCT-TNBC trial)
por: Hilton, John, et al.
Publicado: (2018)

Radium-223 for the Management of Bone Metastases in Castration-Resistant Prostate Cancer
por: Cox, Heather, et al.
Publicado: (2015)

Bone-Targeted Agents for the Management of Breast Cancer Patients with Bone Metastases
por: Simos, Demetrios, et al.
Publicado: (2013)

Pain in castration-resistant prostate cancer with bone metastases: a qualitative study
por: Gater, Adam, et al.
Publicado: (2011)

Treatment of castration-resistant prostate cancer and bone metastases with radium-223 dichloride
por: Lien, Lise Marie E, et al.
Publicado: (2015)

Impact of Extraskeletal Metastases on Skeletal-Related Events in Metastatic Castration-Resistant Prostate Cancer with Bone Metastases
por: Lobo-Martins, Soraia, et al.
Publicado: (2020)

A primer of bone metastases management in breast cancer patients
por: Petrut, B., et al.
Publicado: (2008)

Incidence and consequences of bone metastases in lung cancer patients
por: Kuchuk, Michael, et al.
Publicado: (2013)

Castration-Resistant Prostate Cancer Tissue Acquisition From Bone Metastases for Molecular Analyses
por: Lorente, David, et al.
Publicado: (2016)

Primary Bankart Repair Versus Arthroscopic Anatomic Glenoid Reconstruction in Patients with Subcritical Bone Loss: A Cost-Utility Analysis
por: Ali, Zakariya S., et al.
Publicado: (2021)

A phase 2 trial exploring the clinical and correlative effects of combining doxycycline with bone-targeted therapy in patients with metastatic breast cancer
por: Addison, C.L., et al.
Publicado: (2016)

When tissue is not the only issue: Poorly differentiated lung squamous-cell carcinoma with adrenal, costochondral, and cardiac metastases – case report
por: Clark, Megan, et al.
Publicado: (2023)

Safety and efficacy of radium-223 dichloride in Japanese patients with castration-resistant prostate cancer and bone metastases
por: Uemura, Hiroji, et al.
Publicado: (2017)

Can routinely collected administrative data effectively be used to evaluate and validate endpoints used in breast cancer clinical trials? Protocol for a scoping review of the literature
por: Shah, Hely, et al.
Publicado: (2023)

Expression of Androgen Receptor Splice Variants in Prostate Cancer Bone Metastases is Associated with Castration-Resistance and Short Survival
por: Hörnberg, Emma, et al.
Publicado: (2011)

Ra-223 Treatment for Bone Metastases in Castrate-Resistant Prostate Cancer: Practical Management Issues for Patient Selection
por: Den, Robert B., et al.
Publicado: (2019)

Impact of Somatic DNA Repair Mutations on the Clinical Outcomes of Bone Metastases from Castration-Resistant Prostate Cancer
por: Cursano, Maria Concetta, et al.
Publicado: (2023)

A randomized trial of individualized versus standard of care antiemetic therapy for breast cancer patients at high risk for chemotherapy-induced nausea and vomiting
por: Clemons, M., et al.
Publicado: (2020)

A Pilot Study of F-18 Fluciclovine-PET/CT as a Diagnostic Tool for Bone Metastases in Patients With Castrate Resistant Prostate Adenocarcinoma and Correlative Analysis of Blood and Bone Molecular Testing (The FACT Study)
por: Babiker, Hani M, et al.
Publicado: (2023)

Bone scan index (BSI) scoring by using bone scintigraphy and circulating tumor cells (CTCs): predictive factors for enzalutamide effectiveness in patients with castration-resistant prostate cancer and bone metastases
por: Hirano, Hisashi, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_btsv76rco1g0ufh26614nob4ma